NCT06159283View on ClinicalTrials.gov

Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment

PHASE2RecruitingINTERVENTIONAL

Enrollment

58

Participants

Timeline

Start Date

March 18, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

COVID-19

Interventions

DRUG

Immunoglobulins

Dosage is Immunoglobulin 1,000mg/kg IV. It administer over 2\~3 days.

Trial Locations (1)

Unknown

RECRUITING

Jaehoon Ko, Seoul

All Listed Sponsors

lead

Jaehoon Ko

OTHER